NCT07143045View on ClinicalTrials.gov

A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases

Not yet recruitingOBSERVATIONAL
Enrollment

800

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2031

Study Completion Date

November 30, 2031

Conditions
EGFR Mutant Advanced Non-small Cell Lung CancerCentral Nervous System (CNS) Metastases
Interventions
DRUG

zorifertinib

Cohort A and B will receive zorifertinib as first line treatment

All Listed Sponsors
lead

Alpha Biopharma (Jiangsu) Co., Ltd.

INDUSTRY

NCT07143045 - A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases | Biotech Hunter | Biotech Hunter